Method Of Preparing Macromolecule Deterrent Surface On a Pharmaceutical Packages

Abstract

A method of preparing a macromolecule deterrent surface on a pharmaceutical package. In particular, the present invention relates to a method of preparing a protein deterrent surface on a pharmaceutical package by applying a coating or coatings directly to the pharmaceutical package that reduces the adsorption of proteins onto pharmaceutical packaging while not affecting the activity of the protein solution contained.

1 - 11 . (canceled) 
     
     
         12 . A pharmaceutical package having a macromolecule deterrent surface prepared by a method comprising:
 depositing a coating that deters macromolecule adsorption onto the surface of a pharmaceutical package by plasma chemical vapor deposition (CVD),   wherein said pharmaceutical package acts as a coating chamber   and   wherein said coating is formed from a precursor compound containing carbon-oxygen bonding,   wherein said coating reduces the adsorption of macromolecules to said surface by >25% compared to the adsorption on the uncoated surface.   
     
     
         13 . A pharmaceutical package according to  claim 12 , wherein said coating is applied with a source of electromagnetic radiation. 
     
     
         14 . A pharmaceutical package according to  claim 12 , wherein said coating is prepared from one or more chemical precursors. 
     
     
         15 . A pharmaceutical package according to  claim 14 , wherein one or more of said precursors are an ether. 
     
     
         16 . A pharmaceutical package according to  claim 14 , wherein one or more of said precursors are an ester. 
     
     
         17 . A pharmaceutical package according to  claim 14 , wherein said precursor contains one or more halogen, alkyl, vinyl, alkynyl, aromatic, hydroxylic, acid, carbonyl, aldehyde, ketone, amine, amino, amide, nitro or sulfonyl derivatized functional groups. 
     
     
         18 . A pharmaceutical package according to  claim 14 , wherein said precursor contains one or more halogen, alkyl, vinyl, alkynyl, aromatic, hydroxylic, acid, carbonyl, aldehyde, ketone, amine, amino, amide, nitro, sulfonyl derivatized functional groups. 
     
     
         19 . A pharmaceutical package according to  claim 14 , where said precursor is a polyether. 
     
     
         20 . A pharmaceutical package according to  claim 19 , wherein said polyether is diglyme, a triglyme, a tetraglyme, a pentaglyme, a hexaglyme, or a functionalized derivative thereof. 
     
     
         21 . A pharmaceutical package according to  claim 14 , wherein said precursor is tetraethylene glycol dimethyl ether. 
     
     
         22 . A pharmaceutical package according to  claim 14 , wherein multiple precursors are deposited either simultaneously or in sequence. 
     
     
         23 . A pharmaceutical package according to  claim 14 , wherein the precursor is applied over a first inorganic oxide layer coating. 
     
     
         24 . A pharmaceutical package according to claim  2 , wherein said inorganic oxide is SiO 2 , TiO 2 , ZrO 2  or Al 2 O 3 . 
     
     
         25 . A pharmaceutical package according to  claim 14 , wherein said precursor is applied over a first adhesion layer. 
     
     
         26 . A pharmaceutical package according to  claim 14 , wherein the precursor is applied over a first barrier layer. 
     
     
         27 . A pharmaceutical package according to  claim 14 , wherein said macromolecule is a naturally occurring or synthetically prepared biomolecule or a derivative thereof in solution or solid state. 
     
     
         28 . A pharmaceutical package according to  claim 27 , wherein one or more macromolecule is a nucleic acid, polynucleotide, protein, peptide, carbohydrate, protein/nucleic acid complex, antibody, vaccine, in solution or solid state. 
     
     
         29 - 31 . (canceled) 
     
     
         32 . A pharmaceutical package having a macromolecule deterrent surface prepared by a method comprising:
 depositing a coating that deters macromolecule adsorption onto the surface of a pharmaceutical package by plasma chemical vapor deposition (CVD),   wherein said pharmaceutical package acts as a coating chamber   and   wherein said coating is formed from a precursor compound containing carbon-oxygen bonding,   wherein said coating is applied with pulsed electromagnetic radiation, with low or high frequency energy of 40-100 kHz, 13.56 MHz or 2.45 GHz.   
     
     
         33 - 42 . (canceled)